Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Am J Respir Crit Care Med
.
2025 Jan 22.
doi: 10.1164/rccm.202406-1143RL.
Online ahead of print.
Authors
Resat Cinar
1
,
Abhishek Basu
2
,
Muhammad Arif
2
,
Joshua K Park
3
,
Charles N Zawatsky
2
,
Ben Long G Zuo
2
,
Mei Xing G Zuo
2
,
Kevin J O'Brien
4
,
Molly Behan
5
,
Wendy Introne
5
,
Malliga R Iyer
3
,
William A Gahl
4
,
May Christine V Malicdan
5
6
,
Bernadette R Gochuico
7
Affiliations
1
National Institute on Alcohol Abuse and Alcoholism, Laboratory of Physiological Studies, Bethesda, Maryland, United States;
[email protected]
.
2
National Institute on Alcohol Abuse and Alcoholism, Section on Fibrotic Disorders, Bethesda, Maryland, United States.
3
National Institute on Alcohol Abuse and Alcoholism, Laboratory of Physiological Studies, Bethesda, Maryland, United States.
4
NIH/NHGRI, Office of the Clinical Director, Bethesda, Maryland, United States.
5
National Human Genome Research Institute Medical Genetics Branch, Section of Human Biochemical Genetics, Bethesda, Maryland, United States.
6
National Human Genome Research Institute, NIH Undiagnosed Diseases Program and Office of Clinical Director, Bethesda, Maryland, United States.
7
AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Maryland, United States.
PMID:
39841973
DOI:
10.1164/rccm.202406-1143RL
No abstract available
Keywords:
Rare Disease; blood biomarker; endocannabinoids; precision medicine; pulmonary fibrosis.